Healthcare use · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Severity of somatic symptoms at end of treatment · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with somatoform disorders and medically unexplained physical symptoms
Psychological therapy showed no clear difference in acceptability 1 ‐ proportion of participants withdrawing during… compared with enhanced or structured care (moderate certainty).
1 finding from 1 review
Dysfunctional cognitions, emotions, or behaviours at end of treatment Whitely Index (different forms) · people with somatoform disorders and medically unexplained physical symptoms
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with depression after stroke
2 findings from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
1 finding from 1 review
Depression: mean scores at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review
Gastrointestinal adverse events · people with depression after stroke
1 finding from 1 review
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Average change in quality of life/satisfaction · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
General functioning ‐ no clinically important change in general functioning · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review